MRI靶向、系统或联合穿刺活检检测临床显著性前列腺癌
本回顾性研究纳入267例PSA≥4 ng/mL且mpMRI显示PI-RADS 3-5病灶的男性,评估MRI靶向、系统或联合前列腺穿刺活检对前列腺癌的诊断效能。联合活检(124/267)较系统活检(87/267)或靶向活检(110/267)单独诊断更多GG≥2前列腺癌,系统活检升级病例中42.1%的癌灶靠近靶向穿刺部位。
要点
- 联合活检较单独靶向或系统活检诊断更多GG≥2前列腺癌。
- 靶向活检较系统活检升级更多GG≥2前列腺癌(P = .0062)。
- 系统活检升级病例中42.1%(24/57)癌灶靠近靶向穿刺部位。
核心结论
- 在PSA≥4 ng/mL且mpMRI显示PI-RADS 3、4或5病灶的男性中,联合活检较单独靶向或系统活检诊断更多前列腺癌;系统活检升级的癌灶靠近或远离靶向穿刺部位可能分别提示活检和mpMRI的改进机会。
研究设计与样本
- 经机构审查委员会批准的回顾性研究,在大型四级医院进行,纳入2015年1月1日至2019年12月31日接受前列腺mpMRI且PSA≥4 ng/mL、mpMRI有活检靶点(PI-RADS 3-5病灶)、MRI后≤6个月内接受联合靶向和系统活检的所有男性,共267例活检(267例患者),分析每例患者最高级别病灶。
诊断标准与关键数值
- 前列腺癌诊断按分级分组(GG;1、2和≥3)评估;最可疑mpMRI病灶PI-RADS 3占18.7%(50/267)、PI-RADS 4占52.4%(140/267)、PI-RADS 5占28.8%(77/267);前列腺癌诊断率68.5%(183/267),其中GG 1占22.1%(59/267)、GG 2占16.1%(43/267)、GG≥3占30.3%(81/267);联合活检诊断GG≥2前列腺癌124/267,系统活检87/267,靶向活检110/267。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: The aim of this study was to assess MRI-targeted, systematic, or combined prostate biopsy for diagnosing prostate cancer to identify opportunities for diagnostic accuracy improvement.
METHODS: This institutional review board-approved, retrospective study, performed at a large, quaternary hospital, included all men undergoing prostate multiparametric MRI (mpMRI) from January 1, 2015, to December 31, 2019, with prostate-specific antigen ≥ 4 ng/mL, biopsy target on mpMRI (Prostate Imaging Reporting and Data System [PI-RADS] 3-5 lesion), and combined targeted and systematic biopsy ≤6 months after MRI. Analysis included the highest grade lesion per patient. The primary outcome was prostate cancer diagnosis by grade group (GG; 1, 2, and ≥3). Secondary outcomes were rates of cancer upgrading by biopsy type and cancer proximity to the targeted biopsy site in patients upgraded by systematic biopsy.
RESULTS: Two hundred sixty-seven biopsies (267 patients) were included; 94.4% (252 of 267) were biopsy naive. The most suspicious mpMRI lesion was PI-RADS 3 in 18.7% (50 of 267), PI-RADS 4 in 52.4% (140 of 267), and PI-RADS 5 in 28.8% (77 of 267). Prostate cancer was diagnosed in 68.5% (183 of 267): 22.1% (59 of 267) GG 1, 16.1% (43 of 267) GG 2, and 30.3% (81 of 267) GG ≥ 3. Combined biopsy (124 of 267) yielded more GG ≥ 2 prostate cancer diagnoses than systematic (87 of 267) or targeted (110 of 267) biopsy alone. More GG ≥ 2 cancers were upgraded by targeted biopsy than by systematic biopsy (P = .0062). Systematic biopsy upgrades were in close proximity to the targeted biopsy site in 42.1% (24 of 57); GG ≥ 3 cancers 62.5% (15 of 24) constituted most proximal misses.
CONCLUSIONS: In men with prostate-specific antigen ≥ 4 ng/mL and PI-RADS 3, 4, or 5 lesion on mpMRI, combined biopsy led to more prostate cancer diagnoses than targeted or systematic biopsy alone. Cancers upgraded by systematic biopsy proximal and distant from the targeted biopsy site may indicate opportunities for biopsy and mpMRI improvement, respectively.
引用
- Burk, Naik, Lacson, et al. MRI-Targeted, Systematic, or Combined Biopsy for Detecting Clinically Significant Prostate Cancer. J Am Coll Radiol. 2023. PMID: 37315913. doi:10.1016/j.jacr.2023.02.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。